Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: A network meta-analysis
Osteoporosis International Apr 12, 2019
Reginster JY, et al. - In this network meta-analysis (NMA), researchers estimated the relative effectiveness of abaloparatide vs other therapies to reduce the risk of fractures in women with postmenopausal osteoporosis (PMO). In all, abaloparatide exhibited the greatest treatment effect relative to placebo in the vertebral fracture (VF) network, the nonvertebral (NVF) network, and the wrist fracture network vs other treatments. Compared with other treatments, abaloparatide had the greatest estimated possibility to prevent the fractures in the following networks: 79% for VF, 70% for NVF, and 53% for wrist fracture.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins